Join

Compare · ACON vs NTRA

ACON vs NTRA

Side-by-side comparison of Aclarion Inc. (ACON) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACON and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
  • NTRA is the larger of the two at $30.57B, about 3695.3x ACON ($8.3M).
  • NTRA has been more active in the news (16 items in the past 4 weeks vs 7 for ACON).
  • NTRA has more recent analyst coverage (25 ratings vs 0 for ACON).
MetricACONNTRA
Company
Aclarion Inc.
Natera Inc.
Price
-
-
Market cap
$8.3M
$30.57B
1M return
-
-
1Y return
-
-
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NASDAQ
IPO
2022
2015
News (4w)
7
16
Recent ratings
0
25
ACON

Aclarion Inc.

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

NTRA

Natera Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Latest ACON

Latest NTRA